Presentation of Vitrolife for the benefit of MediCult's shareholders

Vitrolife AB (publ) ("Vitrolife") invites the shareholders of
MediCult a/s ("MediCult") (OSE: MEC) to attend a presentation by
Vitrolife's CEO, Magnus Nilsson.
 
On Wednesday 28 January 2009 at 12.00 CET, Mr. Nilsson will give a
presentation of Vitrolife and its products for the benefit of the
shareholders of MediCult. In addition, Mr. Nilsson will give his
views on the proposed combination of Vitrolife and MediCult.
Refreshments will be served.
 
Location:
Carnegie Conference Centre, Stranden 1B, 3.etg, Oslo.
 
Please email ah@carnegie.no if you are interested in attending the
presentation.
 
Queries should be addressed to:
Anita Ahlqvist, CEO Assistant, phone +46 31 721 80 83
 
________________________________________________________________________________________
 
Vitrolife is a global biotechnology/medical device Group that works
with developing, manufacturing and selling advanced products and
systems for the preparation, cultivation and storage of human cells,
tissue and organs. The company has business activities within three
product areas: Fertility, Transplantation and Stem Cell Cultivation.
The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as
needles and pipettes, for the treatment of human infertility. The
Transplantation product area works with solutions and systems to
evaluate and maintain organs outside the body in order to select
usable organs and keeping them in optimal condition while waiting for
transplantation. The Stem Cell Cultivation product area works with
media and instruments to enable the use and handling of stem cells
for therapeutic purposes.
Vitrolife today has approximately 150 employees and its products are
sold in more than 80 markets. The company is headquartered in
Gothenburg, Sweden, and there are subsidiaries in USA, Australia,
France and Italy. Production facilities are located in Sweden and the
USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small
Cap.
_________________________________________________________________________________________
 
Vitrolife AB (publ)
Box 9080
SE-400 92 Göteborg
Sweden
Corporate identity number 556354-3452
Tel: +46 31 721 80 00
Fax: +46 31 721 80 90
E-mail: info@vitrolife.com
Homepage: www.vitrolife.com
 
This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.